{"entity":{"id":"remix-therapeutics","kind":"company","name":"Remix Therapeutics","aka":["Remix Therapeutics, Inc."],"tldr":"Remix Therapeutics is a Massachusetts biotech that makes small molecules to change how RNA is processed; REM-422 destroys the messenger RNA for the transcription factor MYB, a driver of adenoid cystic carcinoma and acute myeloid leukaemia.","summary":"Remix Therapeutics uses its REMaster platform to design small molecules that reprogramme RNA splicing and stability. REM-422 induces a poison exon in MYB mRNA, marking it for degradation and lowering MYB protein; it is in phase 1 trials in adenoid cystic carcinoma and in acute myeloid leukaemia and higher-risk myelodysplastic syndromes. The company has partnerships with Janssen and Roche on other RNA-processing targets.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.remixtx.com/"}],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["rem-422"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Watertown, Massachusetts","country":"US","companyType":"biotech","website":"https://www.remixtx.com/","founded":2019,"investors":[],"funding":[]},"route":"/companies/remix-therapeutics/","neighbours":{"drug":[{"id":"rem-422","kind":"drug","name":"REM-422","route":"/drugs/rem-422/"}]}}